IceCure Medical (NASDAQ:ICCM) Upgraded at Alliance Global Partners

Alliance Global Partners upgraded shares of IceCure Medical (NASDAQ:ICCM) to a strong-buy rating in a report released on Friday morning, Zacks.com reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.50 target price on shares of IceCure Medical in a report on Thursday, September 12th.

IceCure Medical Price Performance

NASDAQ ICCM opened at $0.85 on Friday. The stock’s 50 day simple moving average is $0.63 and its 200 day simple moving average is $0.78. IceCure Medical has a one year low of $0.48 and a one year high of $1.57. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.54 and a current ratio of 2.97.

IceCure Medical (NASDAQ:ICCM) last announced its earnings results on Tuesday, August 20th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. IceCure Medical had a negative return on equity of 111.27% and a negative net margin of 410.22%. The company had revenue of $1.01 million for the quarter, compared to analysts’ expectations of $0.90 million. During the same quarter in the prior year, the business earned ($0.09) earnings per share. Sell-side analysts anticipate that IceCure Medical will post -0.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC purchased a new stake in IceCure Medical Ltd (NASDAQ:ICCM) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned 0.15% of IceCure Medical as of its most recent SEC filing. 0.62% of the stock is owned by institutional investors and hedge funds.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.